Mercaptopurine Tablets is a nucleoside metabolic inhibitor indicated for treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.
From the U.S. FDA-approved label for Mercaptopurine. Full label: DailyMed.
Mercaptopurine Tablets is a nucleoside metabolic inhibitor indicated for treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.
From the U.S. FDA-approved label for Mercaptopurine. Full label: DailyMed.
The recommended starting dose of Mercaptopurine Tablets is 1.5 mg/kg to 2.5 mg/kg orally once daily as part of a combination chemotherapy maintenance regimen. Adjust dose to maintain desirable absolute neutrophil count and for excessive myelosuppression. Renal Impairment: Use the lowest recommended starting dose or increase the dosing interval.
Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.
Myelosuppression: Monitor complete blood count (CBC) and adjust the dose of Mercaptopurine Tablets for excessive myelosuppression. Consider testing in patients with severe myelosuppression or repeated episodes of myelosuppression for thiopurine S-methyltransferase (TPMT) or nucleotide diphosphatase (NUDT15) deficiency. Patients with homozygous or homozygous TPMT or NUDT15 deficiency may require a dose reduction. Hepatotoxicity: Monitor transaminases, alkaline phosphatase and bilirubin. Withhold Mercaptopurine Tablets at onset of hepatotoxicity.
Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.
The following clinically significant adverse reactions are described elsewhere in the labeling: Myelosuppression Hepatotoxicity Immunosuppression Treatment related malignancies Macrophage activation syndrome The most common adverse reaction (>20%) is myelosuppression, including anemia, leukopenia and thrombocytopenia.
Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.
7 products from 7 makers in the NepalDoc medicine catalog use this generic:
| Brand | Composition | Maker | Pack |
|---|---|---|---|
| Biopurin 50mg Tablet | Mercaptopurine (50mg) | Neova Biogene Private Limited | strip of 10 tablets |
| Captomer 50mg Tablet | Mercaptopurine (50mg) | Neon Laboratories Ltd | strip of 10 tablets |
| Empurine 50mg Tablet | Mercaptopurine (50mg) | Dabur India Ltd | strip of 10 tablets |
| Mercapto 50mg Tablet | Mercaptopurine (50mg) | Chandra Bhagat Pharma Pvt Ltd | strip of 10 tablets |
| Merkglob 50mg Tablet | Mercaptopurine (50mg) | Globela Pharma Pvt Ltd | strip of 10 tablets |
| Puri Nethol 50mg Tablet | Mercaptopurine (50mg) | GlaxoSmithKline Consumer Healthcare | strip of 10 tablets |
| Purinetone 50mg Tablet | Mercaptopurine (50mg) | Vhb Life Sciences Inc | strip of 10 tablets |
Brand list from the NepalDoc medicine catalog. Availability varies by pharmacy — call ahead to confirm stock.
Store at 20°C to 25°C (68°F to 77°F).
Storage information from the U.S. FDA-approved label.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. NLEM listing does not guarantee that a medicine is in stock at any pharmacy.
